Evidence map›Paper›PMID 41105435›Full record

SynthesisBiomarkers in medicine2025

Diagnostic valuation of MMP family members as biomarkers for pancreatic cancer: a systematic review and meta-analysis.

Mengyuan Lu, Donglin Jiang, Jiaxin Zhang, Ling Liu, Yajing Shen, Tiandong Li, Peng Wang, Jianxiang Shi, Keyan Wang, Hua Ye

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mengyuan LuCollege of Public Health, Zhengzhou University, Zhengzhou, China.
Donglin JiangCollege of Public Health, Zhengzhou University, Zhengzhou, China.
Jiaxin ZhangDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.
Ling LiuCollege of Public Health, Zhengzhou University, Zhengzhou, China.
Yajing ShenCollege of Public Health, Zhengzhou University, Zhengzhou, China.
Tiandong LiCollege of Public Health, Zhengzhou University, Zhengzhou, China.
Peng WangHenan Key Laboratory of Tumor Epidemiology and State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, China.
Jianxiang ShiHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Keyan WangHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Hua YeCollege of Public Health, Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are numerous controversies surrounding the diagnosis of matrix metalloproteinases (MMPs) in pancreatic cancer (PC). Consequently, this study conducts the first comprehensive meta-analysis evaluating the diagnostic performance of MMP family members in PC, highlight potential biomarkers, and investigate sources of heterogeneity.

methodArticles on the MMP family and PC diagnosis were retrieved from PubMed and Web of Science. Diagnostic accuracy was assessed using sensitivity (SEN) and specificity (SPE). Threshold effects, heterogeneity (via meta-regression and subgroup analyses), and result robustness (via sensitivity analysis) were evaluated. Publication bias was examined using Deeks' funnel plot.

resultThis meta-analysis included 48 studies from 23 articles, covering 12 types of MMP. The aggregated SEN, SPE, and area under the curve (AUC) for MMPs in diagnosing PC ranged from 0.61 to 0.76, 0.66 to 0.78, and 0.7273 to 0.8840, respectively. Meta-regression identified sample type as a major contributor to heterogeneity, with tissue-based MMPs showing markedly superior diagnostic performance compared to serum or plasma-based assays. Overall, MMPs showed potential diagnostic value, but their accuracy remains moderate and requires further validation in larger, well-designed studies.

conclusionMMPs represent potential candidates for PC diagnosis, but current evidence is insufficient for clinical application, requiring further prospective studies.

Indexed as

Biomarkers, TumorMatrix MetalloproteinasesPancreatic NeoplasmsHumansBiomarkers, TumorMatrix Metalloproteinasesdiagnostic biomarkerdiagnostic valuemeta-analysisMMP familypancreatic cancer

Identifiers

PMID41105435
PMCPMC12542613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.